Frequently Asked Questions
Planning to submit a project?
Find answers about eligibility, funding, evaluation, and the application process.
This call is open to Tel Aviv University (TAU) faculty members and affiliated researchers conducting research in human disease-related biology.
Projects should demonstrate:
- Strong scientific innovation
- Clear clinical relevance and unmet medical need
- Potential for drug discovery translation
- Alignment with BCDD infrastructure, expertise, and capabilities
The BCDD provides in-kind support of up to USD 50,000 per project, primarily for:
- Screening activities
- Proof-of-concept studies
- Use of BCDD platforms, technologies, and professional staff
All funded work is conducted within the BCDD and designed jointly with BCDD scientists.
The selection process includes two stages:
- Preproposal submission
- Full proposal invitation for selected preproposals, followed by:
Review by the BCDD Scientific Advisory Board and BCDD team
Written feedback to all full-proposal applicants
- Preproposal deadline: March 15, 2026
- Preproposal notification: April 23, 2026
- Full proposal deadline: May 24, 2026
- Funding decision: June 25, 2026
Applicants will be asked to provide:
- Project title
- Researcher name(s) and affiliation
- Field of invention
- Suggested therapeutic indication
- Project objectives and scientific rationale
- Experimental models and proposed approach
- Potential clinical relevance and competitive landscape
Yes. Collaborative proposals involving more than one researcher are welcome, provided they meet the scientific and translational criteria.
For scientific or administrative inquiries, please contact the BCDD team via the designated contact channel on this portal.
